IFNL3 and chronic obstructive pulmonary disease: Circulating IFNL3 was detectable in 3.6% (19/528) of the COPD patients during stable phase and in 7.2% (32/446) of the COPD patients during the exacerbation phase whereas it was detectable in 80% (24/30) of the blood samples from healthy controls.